MYC and melanoma: For example, regarding overexpression of bromodomain containing (BRD4) and c-Myc in melanoma and hepatocellular carcinoma, thus, ARV-825, a proteolysis targeting chimera that specifically targets BRD4 and c-Myc was designed for anticancer therapy [32–34].